The goal of this pre-post study is to assess the risk of hyperkalemia in adults with hypertension on medication in Bangladesh. The main questions it aims to answer are: Is the risk of hyperkalemia after the initiation of Low Sodium Salt Substitute (LSSS) in people on antihypertensive medication (especially RASi) large enough to be concerned about its broad use in this population? Does initiation of LSSS correct hypokalemia in people on antihypertensive medication (especially RASi) with low serum potassium levels? Participants will be asked to reduce overall salt intake and to use LSSS on every occasion where regular salt would normally be used, including as cooking salt.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
607
The low sodium salt substitute contains 25% potassium chloride (KCl range; 20%-35%)
The National Heart Foundation of Bangladesh
Dhaka, Bangladesh
RECRUITINGIncident hyperkalemia (K ≥5.5 mmol/L)
Time frame: 4 and 8 weeks
Proportion of the correction of hypokalemia (from K <3.5 mmol/L to 3.5-5.0 mmol/L)
Time frame: 4 and 8 weeks
Change in serum potassium levels
Time frame: 4 and 8 weeks
Change in systolic and diastolic blood pressure (mmHg)
Time frame: 4 and 8 weeks
Number of Participants Adherent to LSSS use
Time frame: 4 and 8 weeks
Sohel Reza Choudhury, MD, PhD
CONTACT
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.